1)Eiseman JL, Eddington ND, Leslie J, et al:Plasma pharmacokinetics and tissue distribution of paclitaxel in CD2F1 mice. Cancer Chemother Pharmacol 34:465-471, 1994
2)Soma D, Kitayama J, Konno T, et al:Intraperitoneal administration of paclitaxel solubilized with poly(2-methacryloxyethyl phosphorylcholine-co n-butyl methacrylate)for peritoneal dissemination of gastric cancer. Cancer Sci 100:1979-1985, 2009
3)Ishigami H, Kitayama J, Otani K, et al:Phase Ⅰ pharmacokinetic study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer. Oncology 76:311-314, 2009
4)Ishigami H, Kitayama J, Kaisaki S, et al:Phase Ⅱ study of weekly intravenous and intraperitoneal paclitaxel combined with S-1 for advanced gastric cancer with peritoneal metastasis. Ann Oncol 21:67-70, 2010
5)Yamaguchi H, Kitayama J, Ishigami H, et al:A phase 2 trial of intravenous and intraperitoneal paclitaxel combined with S-1 for treatment of gastric cancer with macroscopic peritoneal metastasis. Cancer 119:3354-3358, 2013
6)Ishigami H, Fujiwara Y, Fukushima R, et al:Phase Ⅲ Trial Comparing Intraperitoneal and Intravenous Paclitaxel Plus S-1 Versus Cisplatin Plus S-1 in Patients With Gastric Cancer With Peritoneal Metastasis:PHOENIX-GC Trial. J Clin Oncol 36:1922-1929, 2018
7)Fujiwara Y, Ishigami H, Miwa H, et al:Phase Ⅱ study of intraperitoneal paclitaxel plus S-1/oxaliplatin for gastric cancer with peritoneal metastasis:SOX+IP PTX trial. J Clin Oncol 34(suppl):Abst. 4040, 2016
8)Aizawa M, Ishigami H, Yabusaki H, et al:Phase Ⅱ study of intraperitoneal paclitaxel plus S-1/paclitaxel for gastric cancer with positive peritoneal cytology:CY-PHOENIX trial. J Clin Oncol 35(suppl):Abst. 96, 2017
9)Kitayama J, Ishigami H, Yamaguchi H, et al:Salvage gastrectomy after intravenous and intraperitoneal paclitaxel(PTX)administration with oral S-1 for peritoneal dissemination of advanced gastric cancer with malignant ascites. Ann Surg Oncol 21:539-546, 2014
10)Ishigami H, Yamaguchi H, Yamashita H, et al:Surgery after intraperitoneal and systemic chemotherapy for gastric cancer with peritoneal metastasis or positive peritoneal cytology findings. Gastric Cancer 20(Suppl 1):128-134, 2017
11)Yamaguchi H, Satoh Y, Ishigami H, et al:Peritoneal Lavage CEA mRNA Levels Predict Conversion Gastrectomy Outcomes after Induction Chemotherapy with Intraperitoneal Paclitaxel in Gastric Cancer Patients with Peritoneal Metastasis. Ann Surg Oncol 24:3345-3352, 2017